AACE is partnering with the American Head and Neck Society Endocrine Surgical Section to bring a full day of thyroid cancer programming to the AACE Scientific & Clinical Congress on Friday.
According to session chair Peter Singer, MD, FACE, the morning session “is going to be 100 percent clinically oriented. This will be directed to the practicing endocrinologist.”
Four speakers make up the morning agenda and will cover key topics, aiming to be both practical and in some cases a bit controversial.
The program will kick off with a look at the worldwide epidemic of thyroid cancer presented by internationally renowned endocrinologist Martin Schlumberger, MD, Professor of Oncology at Institute Gustave Roussy.
“Dr. Schlumberger has written many of the studies on radioactive iodine treatment and chemotherapy for thyroid cancer. He will be talking about the increased prevalence of thyroid cancer in the world. This will be an up-to-date, state of the art lecture on the significant problem of the increasing incidence of thyroid cancer worldwide,” said Greg Randolph, MD, FACS, FACE, Professor of Otolaryngology Head and Neck surgery and Claire and John Bertucci Endowed Chair in Thyroid Surgical Oncology Harvard Medical School who is co-chairing the afternoon program.
This lecture will be followed by a discussion on the pitfalls and advances in the management of advanced thyroid cancer by Naifa Busaidy, MD, FACP, FACE, Associate Professor at The University of Texas MD Anderson Cancer Center.
“Dr. Busaidy is going to talk about how we treat more advanced thyroid cancer. There are a number of therapies, all of which have side effects. But there are many others in the pipeline. Dr. Busaidy will discuss how and when to begin treating those patients and the outcomes,” said Dr. Singer.
One of the more controversial topics to be discussed involves the recent reclassified subsection of papillary thyroid cancer to a benign lesion category called noninvasive follicular thyroid neoplasm with papillary-like nuclear features or NIFTP. Dr. Randolph will look at NIFTP from a surgeon’s perspective.
“It was formerly called a malignancy, and so we have carved that out of the low risk thyroid cancer landscape and defined it as a benign lesion. I’ll be discussing the manifestations of this new accepted terminology,” he said.
The morning will wrap up with a review of surgical management of higher risk thyroid cancers by Amy Chen, MD, MPH, FACS, Willard and Lillian Hackerman Professor of Otolaryngology, Head and Neck Surgery at Emory University School of Medicine.
“The morning sessions will provide an appreciation of the increasing incidence of thyroid cancer and its meaning, an appreciation of the wide range of low risk lesions and how to optimally manage them, and an appreciation of the surgical options for all the different types of thyroid cancers including those with favorable and those with less favorable prognosis,” said Dr. Randolph.
Drs. Singer, Randolph, Schlumberger and Busaidy will be joined by David Terris, MD, FACS, FACE, Brendan Stack Jr., MD, FACS, FACE, and Catherine Sinclair, MD, FRACS, in the afternoon for a multidisciplinary tumor board panel, moderated by Jeffrey Mechanick, MD, FACN, FACE, ECNU, and Dr. Randolph. There will be a formal presentation of interesting case studies covering the spectrum of thyroid cancer ranging from those that are very indolent which may be observed, those that are associated with lower morbidity and mortality and require treatment to those thyroid cancers that are more severe and associated with significant morbidity and mortality despite aggressive treatment.
“The audience will be exposed to the full gamut of presentation and natural histories with thyroid cancer and hopefully leave the conference with better understanding of these disorders,” said Dr. Mechanick.
Following the tumor board panel discussion, a light-hearted round of Thyroid Cancer Jeopardy will conclude the program with members of the panel participating by answering questions from a variety of categories and difficulty levels.
“Some of them will be trivial, others will be management oriented and basically cover the full spectrum of information that was presented during the course of the day,” added Dr. Mechanick.
Session Notes: F51: Thyroid Cancer 2018: A Collaborative Program between AACE, ACE and the American Head and Neck Society Endocrine Surgical Section – Key Topics in Thyroid Cancer 9:15 am on Friday in Room 312 Peter Singer, MD, FACE, is chairing the session.
F52: Thyroid Cancer 2018: A Collaborative Program between AACE, ACE and the American Head and Neck Society Endocrine Surgical Section – Multidisciplinary Tumor Board Panel & Thyroid Cancer Jeopardy 2:15 pm on Friday in Room 207 Jeffrey Mechanick, MD, FACN, FACE, ECNU and Gregory Randolph, MD, FACS, FACE, are co-chairs.